Sign In
Last checked at 
21 Apr 2026 07:00
21 April 2026
TheraCryf plc
("TheraCryf", the "Company" or the "Group")
Investor Webinar
TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces that Dr Huw Jones, Chief Executive Officer and Dr Helen Kuhlman, Chief Operating Officer, will host an investor webinar on Friday, 24 April 2026 at 10.00 am (BST).
The webinar will focus on the Company's recent announcements, including progress in its lead orexin-1 (Ox-1) receptor antagonist programme for addiction as it moves towards clinical readiness, alongside broader strategic developments as TheraCryf advances Ox-1 towards first-in-human studies.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until Thursday, 23 April 2026, 9.00 am (BST), or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet TheraCryf via: https://www.investormeetcompany.com/theracryf-plc/register-investor
Investors who already follow TheraCryf on the Investor Meet Company platform will automatically be invited.
-Ends-
Enquiries
TheraCryf plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, COO
| +44 (0)1625 315 090 enquiries@theracryf.com |
Singer Capital Markets (NOMAD & Joint Broker) Phil Davies / Patrick Weaver
| +44 (0)20 7496 3000 |
Turner Pope Investments (Joint Broker) Guy McDougall / Andy Thacker
| +44 (0)20 3657 0050
|
Northstar Communications (Investor Relations) Sarah Hollins | +44 (0)113 730 3896 sarah@northstarcommunications.co.uk
|
About TheraCryf
TheraCryf plc is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of significant unmet medical need within central nervous system (CNS) disorders.
The Group's lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders.
The programme has already been heavily de-risked for both safety/tolerability and efficacy in previous testing and is fully funded through final pre-clinical trials to clinical readiness, with regulatory submissions for first in man studies targeted for 2026.
TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01.
The Group operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with commercially focused pharmaceutical and biotechnology companies.
TheraCryf's headquarters and registered office are at Alderley Park, Cheshire.
For further information, visit: https://theracryf.com
Follow the stocks
